| SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR | None | ||
| 400MG;100MG;100MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| VOSEVI is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. o Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor. | |||
|
Yes
| |||
| VOSEVI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||||||||||||||||||||||
| ********** *************** ******** | ********** *************** ******** | ********** *************** ******** | ********** *************** ******** | ********* ********* | ********* ********* | ********** *************** ******** | ********** *************** ******** | ********** **************** | ********** **************** | ********** **************** | ********** **************** | ********** *************** ******** | ********** *************** ******** | ************ *** ******* *** ******** ********* * ***** | ************ *** ******* *** ******** ********* * ***** | ********* ********* | ********* ********* | ********* ********* | ********* ********* | ********** *************** ******** | ********** *************** ******** | ********** *************** ******** | ********** **************** | ********** **************** | ********** ** ********* * ***** | ********** *************** ******** | ********* ********* | *********** *********** ** ***** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** ***** ********* ********* | *********** *********** ** ***** ********* ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|